Fischer Medical Ventures has entered the advanced diagnostic imaging segment through its wholly owned subsidiary, Time Medical International Ventures (India) Private Ltd. The launch of the CLARION 64/128-Slice AI-Driven CT System at the India Health Expo 2026 marks a strategic expansion into high-performance medical hardware.

The event was formally inaugurated by Dr. Sunil K. Khetrapal, Deputy Director General of the Association of Healthcare Providers India (AHPI). The presence of senior healthcare administrators signals industry validation for the platform’s focus on intelligent clinical workflows and sustainable healthcare delivery.

Product Specifications

The CLARION platform integrates high-performance imaging hardware with artificial intelligence to support diagnostic precision and operational efficiency. Key technical features include:

Clinical Configurations

The system is available in scalable configurations tailored to specific clinical requirements:

• 64-Slice Configuration: Features a 91 cm bore, suitable for vascular imaging and intraoperative applications.
• 128-Slice Configuration: Supports advanced procedures requiring higher temporal resolution, including cardiac, neurological, and thoracic imaging.

Interventional Capabilities

Beyond conventional diagnostics, the CLARION platform extends into interventional and surgical environments. The Big Bore CT-on-Rail configuration enables mobility between clinical scenarios and supports hybrid operating room integration. Advanced capabilities such as 4D CT phased acquisition assist in respiratory monitoring and tumor targeting during radiotherapy by reducing motion-related artifacts.

Strategic Context

Time Medical International Ventures specializes in the design and manufacture of high-performance MRI systems. The introduction of the CLARION CT system reinforces the group’s commitment to building a comprehensive medical imaging ecosystem that combines engineering innovation with AI-driven workflows.

Shankar Varadharajan and his Persons Acting in Concert (PACs) have further increased their aggregate shareholding in Fischer Medical Ventures Limited to 63.08% of the total voting capital, following an additional acquisition of shares via warrant conversion. This latest transaction, completed on August 17, 2026, involved the preferential allotment of 4,54,210 equity shares to FMV Holdings Pte Ltd. Mr. Varadharajan’s individual holding remains unchanged at 12.31%, while FMV Holdings Pte Ltd increased its stake from 50.74% to 50.78%. This move completes the conversion of all warrants held by the promoter group, consolidating their control over the Chennai-based medical device manufacturer.

The disclosure was filed under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, with both the BSE Limited and the National Stock Exchange of India Limited. The acquisition was executed through the conversion of the remaining warrants held by FMV Holdings Pte Ltd into equity shares. Consequently, FMV Holdings’ warrant holdings decreased from 4,54,210 to 0. Mr. Varadharajan and Mr. Ravindran Govindan saw no change in their equity or warrant positions during this specific transaction.

Shareholding Structure Post-Acquisition

The table below details the updated shareholding pattern of the acquirer and PACs:

Post-acquisition, the promoter group holds no warrants or other convertible instruments. There are no encumbrances, pledges, or liens on any of the shares held by the acquirer or PACs.

Capital Structure Changes

The acquisition resulted in a final increase in the company’s issued equity capital. Prior to this allotment, Fischer Medical Ventures Limited’s equity share capital stood at ₹69,82,31,260, divided into 69,82,31,260 equity shares of Re. 1 each. Following the conversion of the remaining warrants, the total equity share capital increased to ₹69,86,85,470, comprising 69,86,85,470 equity shares. The total diluted share/voting capital now matches the basic equity capital at ₹69,86,85,470, as there are no outstanding convertible securities.

What the Numbers Show

The complete conversion of all outstanding warrants by the promoter group eliminates future dilution risk for minority shareholders associated with these instruments. With the promoter group now holding a two-thirds majority in voting rights (63.08%) and zero convertible securities, the capital structure is stabilized. The alignment of basic and diluted voting capital indicates that no further equity dilution will occur from existing warrant conversions, providing clarity on the promoter group's consolidated control over corporate governance decisions.